Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more
Location: 331 Oyster Point Boulevard, Suite 150, South San Francisco, CA, 94080, United States | Website: https://pliantrx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
71.21M
52 Wk Range
$1.10 - $16.10
Previous Close
$1.16
Open
$1.16
Volume
1,440,178
Day Range
$1.13 - $1.26
Enterprise Value
-174.3M
Cash
305.6M
Avg Qtr Burn
-43.52M
Insider Ownership
3.04%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bexotegrast (PLN-74809) Details Primary sclerosing cholangitis | Phase 2a Update | |
PLN-101095 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
PLN-101325 Details Duchenne muscular dystrophy | Phase 1 Data readout | |
Failed Discontinued | ||
Bexotegrast (PLN-74809) Details Idiopathic pulmonary fibrosis | Failed Discontinued |